EyePoint Pharmaceuticals ... (EYPT)
NASDAQ: EYPT
· Real-Time Price · USD
10.24
-0.13 (-1.25%)
At close: Jun 27, 2025, 9:37 AM
-1.25% (1D)
| Bid | 10.24 |
| Market Cap | 704.63M |
| Revenue (ttm) | 56.04M |
| Net Income (ttm) | -146.78M |
| EPS (ttm) | -2.42 |
| PE Ratio (ttm) | -4.23 |
| Forward PE | -3.6 |
| Analyst | Buy |
| Ask | 10.34 |
| Volume | 19,239 |
| Avg. Volume (20D) | 831,977 |
| Open | 10.28 |
| Previous Close | 10.37 |
| Day's Range | 10.20 - 10.30 |
| 52-Week Range | 3.91 - 13.99 |
| Beta | 1.64 |
About EYPT
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol EYPT
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for EYPT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
EyePoint Pharmaceuticals Inc. is scheduled to release its earnings on Aug 6, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 weeks ago
+18.12%
EyePoint shares are trading higher after the compa...
Unlock content with
Pro Subscription
4 months ago
+2.36%
EyePoint Pharmaceuticals shares are trading higher after the company announced six-month results for its Phase 2 VERONA trial and stated the trial met its primary endpoint.
2 weeks ago · seekingalpha.com
EyePoint Stock: Retaining My 'Risky Buy' Call - Pivotal Data Due Early 2026EyePoint Pharmaceuticals, Inc.'s Duravyu shows promising Phase 2 results in DME, supporting a slightly risky 'Buy' call ahead of pivotal Phase 3 readouts in 2026. Duravyu's potential for less frequent...
1 month ago · seekingalpha.com
EyePoint Pharmaceuticals, Inc. (EYPT) Q1 2025 Earnings Call TranscriptEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT ) Q1 2025 Earnings Conference Call May 7, 2025 8:30 AM ET Company Participants George Elston - Executive Vice President & Chief Financial Officer Jay Duker ...
